ACCESS PHARMACEUTICALS Explosionsgefahr?

Mugard bereits zugelassen!!! Hier fliessen bald Milestones!!!


Development team at Access Pharmaceuticals is interested in identifying out-licensing candidates, as well as alliance and merger opportunities for for our oncology and dermatology products, as well as for our nanopolymer technologies, including Cobalamin™ for oral drug delivery, Cobalamin™ for disease targeting, and SEPA, Access’ nail and transdermal drug delivery technology.

MuGard™ is our product for oral mucositis which has received US FDA marketing allowance. Access has licensing agreements with Milestone Biosciences (North America), SpePharm (Europe) and RHEI Pharmaceuticals (certain Asian territories), and is seeking commercial partners in other territories.

Access has exclusive worldwide rights to the oncology applications of phenylbutyrate (PB), a histone deacetylase (HDAC) inhibitor. Access is seeking licensing and commercialization partners for use of PB in cancer therapy and for the topical treatment of radiation proctitis.

ProLindac™ is our major chemotherapeutic compound, currently in Phase 2 clinical development. Access has licensed ProLindac to Nanjing Aosaikang Medicinal Group Co., Ltd for development and commercialization in China, and is seeking codevelopment partners for other territories.

Angiolix®, Alchemix®, and Prodrax® are anticancer products in preclinical development, while thiarabine is a novel nucleoside in phase 2 clinical development. Pexiganan is a phase 3 cream product for the treatment of diabetic foot ulcers and EcoNail is a phase 2 nail lacquer for treatment of onychomycosis.

We are open to discussing arrangements of all types. To learn more about our products and capabilities please contact Phillip Wise by sending an email to the address below.


interessante Pipeline!!!

Senior Management

Jeffrey B. Davis, Chief Executive Officer

President, SCO Financial Group LLC.
Senior Vice President and Chief Financial Officer of a healthcare technology company.
Vice President, Corporate Finance, at Deutsche Morgan Grenfell.
Senior marketing and product management positions at AT&T Bell Laboratories.
Marketing and Product Manager at Philips Medical Systems North America.
MBA, The Wharton School, University of Pennsylvania.
BS Biomedical Engineering, Boston University.


ist President der SCO Financial Group


finance.yahoo.com/q/it?s=ACCP.OB

das Müssten die insider sein

Royaltis für MuGard!!! Bei Peak Sales von 350 Mio  = 70 Mios Cash in die täsch!!

MK ca 48 Mio Dollar

Shares ca 22 Mio

einfach mal anschauen!!! Cash sind wohl noch ca 2,7 Mille da? In Erwartung der Royaltis dürfte es aber allemal reichen!

suche.aol.de/aol/...amp;u=http%3A%2F%2Fwww.accesspharma.com%2F

Gruss Macos

von Griffin
www.stockshaven.com/wp-content/themes/...s/griffinresearch.pdf


und
www.mffais.com/accp.ob

seekingalpha.com/article/...ng-to-advance-pipeline?source=feed

suche.aol.de/aol/...2FAccess-Pharmaceuticals-Inc%2F81551838225

gibts schon zu Kaufen!!!

www.docmorris.de/de/suche/produkte/...laschen/474079?filters=

dann müssten ja bald die ersten Zahlungen fliessen???

hat die Lizenz für Nordamerika!

Was ist das denn fürn ne Bude???
das gefällt mir gar nicht!!!
suche.aol.de/aol/...334&u=http%3A%2F%2Fmilestonebio.com%2F

soll Mugard auf dem chinesischen markt erhältlich sein?

suche.aol.de/aol/...Finvestorsandmedia%2Freleases%2F021908.htm

In a therapeutic study comparing thiarabine to methotrexate, a commonly used clinical drug for RA treatment, high resolution 3-D images from an X-ray microtomograph were used along with histological scoring to evaluate joint and bone destruction. Thiarabine demonstrated statistically significant anti-arthritic efficacy comparable to that of methotrexate. "The images from X-ray microtomography present a compelling visual representation of diseased vs. treated limbs" commented David Nowotnik, Senior Vice President Research and Development. "We are delighted with the results of the preclinical study which demonstrate a real benefit to the use of thiarabine in RA."

"Our current development focus for thiarabine is for the treatment of hematological cancers," stated Jeffrey B. Davis, President & CEO. "But, we believe these new RA data provide compelling evidence that Thiarabine should be developed for rheumatoid arthritis as well."

Thiarabine is a next generation nucleoside analogue that Access has licensed from Southern Research. It has been in two Phase 1/2 solid tumor trials and was shown to have significant anti-tumor activity. Access is now working with leukemia and lymphoma specialists to initiate additional Phase 2 clinical trials in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and other indications. "The IND for thiarabine has been transferred to Access and we have a supply of clinical-grade material." continued Dr. Nowotnik. "We should be able to start the study shortly after FDA clearance of the protocol and drug recertification."

Access is actively seeking co-development partners for all applications of Thiarabine.

About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


   Contact: Company                Contact: Investor Relations
   Stephen B. Thompson             Donald C. Weinberger/Diana Bittner (media)
   Vice President                  Wolfe Axelrod Weinberger Assoc. LLC
   Chief Financial Officer        (212) 370-4500
   Access Pharmaceuticals, Inc.
finance.yahoo.com/news/...-prnews-4208247497.html?x=0&.v=1

www.losangeleschronicle.com/articles/view/108780

www.facebook.com/...65&comments=1&ref=mf#s125670367165


Gruss Macos

blog.qualitystocks.net/?p=16289

aber alles drin was man wissen mus!!

seekingalpha.com/article/...ine-shallow-valuation?source=yahoo

Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference
Access to Provide Details on MuGard Launch in Europe

finance.yahoo.com/news/...-prnews-2448465290.html?x=0&.v=1

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
PREVENTION OF ORAL MUCOSITIS EXPANDS MARKET POTENTIAL TO MULTIPLE BILLIONS OF DOLLARS

finance.yahoo.com/news/...-prnews-3941187419.html?x=0&.v=1

Wird Zeit das der Partner in US mal endlich loslegt, oder wie stellen sie sich das dort vor?

Ein Pharmaladen von vielen, aber durchaus interessant. Deine Recherche ist jedenfalls klasse!

nicht mehr..;-) Danke, stell nur ab und zu ne news rein, ist dann nicht ganz so langweilig!

Gute fundierte Berichte.

Verdammt jetzt weiss ich nicht, was ich beim nächsten Rücksetzer kaufen soll.... Antigenics inc oder Genta oder Acces Pharmaceuticals????

Scheisse gibt ja mehr Pharmafirmen als Zecken=(

Mach weiter so richtig gut

ich Dir auch nicht bei helfen! Genta ist nen Zock. Antigenics kenn ich nicht!

hast du hier shares? oder bist einfach auf dem Beobachterposten?

Ich wollte hier noch aufspringen aber jetzt lohnt es sich wahrscheinlich net mehr

grüße

Wochen  zwei mal gekauft!  Wie weit es jetzt geht weiss ich auch nicht....könnte mir aber einen Durchmarsch bis an die 10 Dollar vorstellen...aber nur wenn Mugard in US anläuft! ausserdem hoffe ich mal das sie jetzt keine Kapitalerhöung machen. Viel interessanter finde ich ProLindac, bei Erfolg Blockbuster!
Money Flow und OBV sehen super aus.
Sammel bei Gelegenheit immer ein Paar ein.

von pro lindac mal posten finde den wert nicht wenn ich den oben bei suche eingebe =)

Werde Acces weiterhin beobachten und Mugard im Auge behalten.

Danke schon mal

Ich sammel ein. was Du machst musste selber entscheiden!

ProLindac ist aus der Pipeline von Acces...:-)))